Key result
Tislelizumab is linked to severe myasthenia gravis and acute myocardial injury with persistent troponin elevation.
Why the study?
PD-1 inhibitors can cause serious immune-related adverse events including myasthenia gravis and myocardial injury, which pose diagnostic challenges during therapy.
Case Report (n=1)
No
Severe PD-1 inhibitor-associated myasthenia gravis can overlap with acute myocardial injury, and persistently elevated hs-cTnT may help identify patients at increased risk for future severe cardiovascular events like STEMI.
Answers are grounded in this paper and cite their sources.
Persistent hs-cTnT elevation after PD-1 inhibitor myasthenia gravis may flag delayed STEMI risk; leaves open whether surveillance improves outcomes.
Background PD-1 inhibitors can cause serious immune-related adverse events, including myasthenia gravis (MG). The occurrence of myocardial injury during immune checkpoint inhibitor therapy can pose diagnostic challenges. Case presentation A 65-year-old man with hepatocellular carcinoma developed severe PD-1 inhibitor-associated MG after receiving tislelizumab. During the acute phase, he developed acute myocardial injury, with marked hs-cTnT elevation and new ST-segment depression on electrocardiography, and non-ST-segment elevation myocardial infarction (NSTEMI) was clinically suspected. His myasthenic symptoms gradually improved with immunosuppressive therapy, whereas hs-cTnT remained elevated during follow-up. Seven months after the initial presentation, he developed an ST-segment elevation myocardial infarction due to total occlusion of the proximal left anterior descending artery and underwent percutaneous coronary intervention. Conclusion This case highlights the need to carefully evaluate the underlying cause of myocardial injury in patients with severe PD-1 inhibitor-associated MG. Persistent hs-cTnT may identify patients at increased cardiovascular risk, although the prognostic significance of this finding requires further investigation.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2026) conducted a case report in Hepatocellular carcinoma, PD-1 inhibitor-associated myasthenia gravis, acute myocardial injury (n=1). Tislelizumab was evaluated. Tislelizumab administration in a 65-year-old man with hepatocellular carcinoma was associated with the development of severe myasthenia gravis and acute myocardial injury with persistent hs-cTnT elevation.
Synapse has enriched 10 related papers. Consider them for comparative context: